title: Small RNAs deliver a blow to ovarian cancer.
abstract: Targeted therapeutic approaches have seen tremendous advances in the last decade, for good reason. Specifically intervening with a disease-causing gene can revert the deleterious phenotype while eliminating the toxicity often associated with broad-spectrum agents. Unfortunately, because these selective agents hit one target in a single location, acquired resistance is often high. An arguably better treatment approach includes coupling multiple targeted agents or using an agent that hits an individual target in several independent locations and/or alters multiple relevant targets in the disease-causing pathway(s), precisely the approach taken by Nishimura and colleagues in their recent report aimed at identifying a better treatment option for ovarian cancer.
authors.affiliation: Department of Molecular, Cellular and Developmental Biology, Yale University, New Haven, Connecticut.
authors.forename: Andrea
authors.initials: A
authors.lastname: Kasinski
authors.forename: Frank J
authors.initials: FJ
authors.lastname: Slack
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D035683:MicroRNAs / Q000627:therapeutic use*; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D034741:RNA, Small Interfering / Q000627:therapeutic use*; D036104:Receptor, EphA2 / Q000037:antagonists & inhibitors*; D036183:Receptor, EphB2 / Q000037:antagonists & inhibitors*
chemical_list: D000970:Antineoplastic Agents; C575048:MIRN520 microRNA, human; D035683:MicroRNAs; D034741:RNA, Small Interfering; D036104:Receptor, EphA2; D036183:Receptor, EphB2